BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999;341:1368-1378. [PMID: 10536130 DOI: 10.1056/nejm199910283411807] [Cited by in Crossref: 655] [Cited by in F6Publishing: 256] [Article Influence: 28.5] [Reference Citation Analysis]
Number Citing Articles
1 Merla A, Liu KG, Rajdev L. Targeted Therapy in Biliary Tract Cancers. Curr Treat Options Oncol 2015;16:48. [PMID: 26266637 DOI: 10.1007/s11864-015-0366-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
2 Keane MG, Horsfall LJ, Rait G, Pereira SP. Sociodemographic trends in the incidence of pancreatic and biliary tract cancer in UK primary care. PLoS One 2014;9:e108498. [PMID: 25268478 DOI: 10.1371/journal.pone.0108498] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
3 Kassahun WT, Günl B, Tannapfel A, Ungemach FR, Hauss J, Abraham G. Alpha1-and beta2-adrenoceptors in the human liver with mass-forming intrahepatic cholangiocarcinoma: density and coupling to adenylate cyclase and phospholipase C. Naunyn Schmiedebergs Arch Pharmacol 2005;372:171-81. [PMID: 16292515 DOI: 10.1007/s00210-005-0017-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
4 Yu X, Zou Y, Li Q, Mao Y, Zhu H, Huang G, Ji G, Luo X, Yu C, Zhang X. Decorin-mediated inhibition of cholangiocarcinoma cell growth and migration and promotion of apoptosis are associated with E-cadherin in vitro. Tumour Biol 2014;35:3103-12. [PMID: 24272200 DOI: 10.1007/s13277-013-1402-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
5 Wang G, Wang Q, Fan X, Ding L, Dong L. The Significance of Adjuvant Therapy for Extrahepatic Cholangiocarcinoma After Surgery. Cancer Manag Res 2019;11:10871-82. [PMID: 31920396 DOI: 10.2147/CMAR.S224583] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
6 Sun D, Ma J, Wang J, Wang L, Zhang S, Chen G, Li X, Cui P, Zheng X, Hu Y. A real-world study of the efficacy and safety of anti-programmed cell death-1 therapy combined with chemotherapy or targeted therapy in patients with advanced biliary tract cancer. J Gastrointest Oncol 2020;11:1421-30. [PMID: 33457011 DOI: 10.21037/jgo-20-562] [Reference Citation Analysis]
7 Rattanasinganchan P, Leelawat K, Treepongkaruna SA, Tocharoentanaphol C, Subwongcharoen S, Suthiphongchai T, Tohtong R. Establishment and characterization of a cholangiocarcinoma cell line (RMCCA-1) from a Thai patient. World J Gastroenterol 2006; 12(40): 6500-6506 [PMID: 17072981 DOI: 10.3748/wjg.v12.i40.6500] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
8 Denlinger CS, Meropol NJ, Li T, Lewis NL, Engstrom PF, Weiner LM, Cheng JD, Alpaugh RK, Cooper H, Wright JJ, Cohen SJ. A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers. Clin Colorectal Cancer 2014;13:81-6. [PMID: 24512954 DOI: 10.1016/j.clcc.2013.12.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
9 Wagner A, Wiedmann M, Tannapfel A, Mayr C, Kiesslich T, Wolkersdörfer GW, Berr F, Hauss J, Witzigmann H. Neoadjuvant Down-Sizing of Hilar Cholangiocarcinoma with Photodynamic Therapy--Long-Term Outcome of a Phase II Pilot Study. Int J Mol Sci 2015;16:26619-28. [PMID: 26561801 DOI: 10.3390/ijms161125978] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
10 Engineer R, Patkar S, Lewis SC, Sharma AD, Shetty N, Ostwal V, Ramaswamy A, Chopra S, Agrawal A, Patil P, Mehta S, Goel M. A phase III randomised clinical trial of perioperative therapy (neoadjuvant chemotherapy versus chemoradiotherapy) in locally advanced gallbladder cancers (POLCAGB): study protocol. BMJ Open 2019;9:e028147. [PMID: 31253621 DOI: 10.1136/bmjopen-2018-028147] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Demorrow S. Progranulin: a novel regulator of gastrointestinal cancer progression. Transl Gastrointest Cancer 2013;2:145-51. [PMID: 24040621 DOI: 10.3978/j.issn.2224-4778.2013.02.02] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
12 Kim YI, Park JW, Kim BH, Woo SM, Kim TH, Koh YH, Lee WJ, Kim CM. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma. Radiat Oncol. 2013;8:292. [PMID: 24359879 DOI: 10.1186/1748-717x-8-292] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
13 Pan QX, Su ZJ, Zhang JH, Wang CR, Ke SY. Glasgow Prognostic Score predicts prognosis of intrahepatic cholangiocarcinoma. Mol Clin Oncol 2017;6:566-74. [PMID: 28413670 DOI: 10.3892/mco.2017.1166] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
14 Yun BR, Lee MJ, Kim JH, Kim IH, Yu GR, Kim DG. Enhancement of parthenolide-induced apoptosis by a PKC-alpha inhibition through heme oxygenase-1 blockage in cholangiocarcinoma cells. Exp Mol Med 2010;42:787-97. [PMID: 20938215 DOI: 10.3858/emm.2010.42.11.082] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
15 Zhan M, Zhao X, Wang H, Chen W, Xu S, Wang W, Shen H, Huang S, Wang J. miR-145 sensitizes gallbladder cancer to cisplatin by regulating multidrug resistance associated protein 1. Tumour Biol. 2016;37:10553-10562. [PMID: 26852750 DOI: 10.1007/s13277-016-4957-6] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
16 Yu Z, Zhu J, Jiang H, He C, Xiao Z, Wang J, Xu J. Surgical Resection and Prognostic Analysis of 142 Cases of Hilar Cholangiocarcinoma. Indian J Surg 2018;80:309-17. [PMID: 32288384 DOI: 10.1007/s12262-016-1581-z] [Reference Citation Analysis]
17 Bunyatov T, Zhao A, Kovalenko J, Gurmikov B, Vishnevsky V. Personalised approach in combined treatment of cholangiocarcinoma: a case report of healing from cholangiocellular carcinoma at stage IV. J Gastrointest Oncol 2019;10:815-20. [PMID: 31392064 DOI: 10.21037/jgo.2019.03.05] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
18 Moseley RH. Biliary tract: . Current Opinion in Gastroenterology 2000;16:431. [DOI: 10.1097/00001574-200009000-00007] [Reference Citation Analysis]
19 Kang MH, Lee WS, Go SI, Kim MJ, Lee US, Choi HJ, Kim DC, Lee JH, Kim HG, Bae KS, Cho JM. Can thymidine phosphorylase be a predictive marker for gemcitabine and doxifluridine combination chemotherapy in cholangiocarcinoma?: case series. Medicine (Baltimore) 2014;93:e305. [PMID: 25526478 DOI: 10.1097/MD.0000000000000305] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 Malaguarnera G, Giordano M, Paladina I, Rando A, Uccello M, Basile F, Biondi A, Carnazzo S, Alessandria I, Mazzarino C. Markers of bile duct tumors. World J Gastrointest Oncol 2011; 3(4): 49-59 [PMID: 21528090 DOI: 10.4251/wjgo.v3.i4.49] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
21 Niazi A, Saif MW. Colon Mass as a Secondary Metastasis from Cholangiocarcinoma: A Diagnostic and Therapeutic Dilemma. Cureus 2016;8:e707. [PMID: 27588228 DOI: 10.7759/cureus.707] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
22 Carroll JE Jr, Hurwitz ZM, Simons JP, McPhee JT, Ng SC, Shah SA, Al-Refaie WB, Tseng JF. In-hospital mortality after resection of biliary tract cancer in the United States. HPB (Oxford) 2010;12:62-7. [PMID: 20495647 DOI: 10.1111/j.1477-2574.2009.00129.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
23 Abdel-Rahman O, Elsayed Z, Elhalawani H. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. Cochrane Database Syst Rev. 2018;4:CD011746. [PMID: 29624208 DOI: 10.1002/14651858.cd011746.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
24 Morris S, Gurusamy KS, Sheringham J, Davidson BR. Cost-effectiveness of preoperative biliary drainage for obstructive jaundice in pancreatic and periampullary cancer. J Surg Res. 2015;193:202-209. [PMID: 25172090 DOI: 10.1016/j.jss.2014.07.060] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
25 Loria F, Loria G, Basile S, Crea G, Frosina L, Di Carlo I. Contrast-enhanced ultrasound appearances of enhancement patterns of intrahepatic cholangiocarcinoma: correlation with pathological findings. Updates Surg. 2014;66:135-143. [PMID: 24802031 DOI: 10.1007/s13304-014-0251-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
26 Rustagi T, Dasanu CA. Risk factors for gallbladder cancer and cholangiocarcinoma: similarities, differences and updates. J Gastrointest Cancer 2012;43:137-47. [PMID: 21597894 DOI: 10.1007/s12029-011-9284-y] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 4.2] [Reference Citation Analysis]
27 Arora M, Bogenberger JM, Abdelrahman A, Leiting JL, Chen X, Egan JB, Kasimsetty A, Lenkiewicz E, Malasi S, Uson PLS, Nagalo BM, Zhou Y, Salomao MA, Kosiorek HE, Braggio E, Barrett MT, Truty MJ, Borad MJ. Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer. Cancer Chemother Pharmacol 2020;85:1063-78. [PMID: 32440762 DOI: 10.1007/s00280-020-04079-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
28 Wiesweg M, Aydin S, Koeninger A, Stein A, Schara U, van Roye C, Hense J, Welt A, Schuler M. Administration of Gemcitabine for Metastatic Adenocarcinoma during Pregnancy: A Case Report and Review of the Literature. AJP Rep 2014;4:17-22. [PMID: 25032054 DOI: 10.1055/s-0034-1368091] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
29 Nimeiri HS, Singh DA, Kasza K, Taber DA, Ansari RH, Vokes EE, Kindler HL. The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium. Invest New Drugs 2010;28:854-8. [PMID: 19669700 DOI: 10.1007/s10637-009-9297-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
30 Makiuchi T, Sobue T, Kitamura T, Sawada N, Iwasaki M, Yamaji T, Shimazu T, Inoue M, Tsugane S. Smoking, Alcohol Consumption, and Risks for Biliary Tract Cancer and Intrahepatic Bile Duct Cancer. J Epidemiol 2019;29:180-6. [PMID: 29760302 DOI: 10.2188/jea.JE20180011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
31 Shi XD, Yu XH, Wu WR, Xu XL, Wang JY, Xu LB, Zhang R, Liu C. Dickkopf-1 expression is associated with tumorigenity and lymphatic metastasis in human hilar cholangiocarcinoma. Oncotarget 2016;7:70378-87. [PMID: 27608843 DOI: 10.18632/oncotarget.11859] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
32 Okami J, Dono K, Sakon M, Tsujie M, Hayashi N, Fujiwara Y, Nagano H, Umeshita K, Nakamori S, Monden M. Patterns of regional lymph node involvement in intrahepatic cholangiocarcinoma of the left lobe. J Gastrointest Surg. 2003;7:850-856. [PMID: 14592657 DOI: 10.1007/s11605-003-0029-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
33 Chen MH, Liang PC, Chang KC, Huang JY, Chang YT, Chang FY, Wong JM, Lin FH. Prototype of biliary drug-eluting stent with photodynamic and chemotherapy using electrospinning. Biomed Eng Online 2014;13:118. [PMID: 25138739 DOI: 10.1186/1475-925X-13-118] [Cited by in Crossref: 5] [Article Influence: 0.6] [Reference Citation Analysis]
34 Thelen A, Scholz A, Benckert C, Schröder M, Weichert W, Wiedenmann B, Neuhaus P, Jonas S. Microvessel density correlates with lymph node metastases and prognosis in hilar cholangiocarcinoma. J Gastroenterol 2008;43:959-66. [PMID: 19107340 DOI: 10.1007/s00535-008-2255-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 68] [Article Influence: 1.9] [Reference Citation Analysis]
35 Tsukagoshi M, Araki K, Yokobori T, Altan B, Suzuki H, Kubo N, Watanabe A, Ishii N, Hosouchi Y, Nishiyama M, Shirabe K, Kuwano H. Overexpression of karyopherin-α2 in cholangiocarcinoma correlates with poor prognosis and gemcitabine sensitivity via nuclear translocation of DNA repair proteins. Oncotarget 2017;8:42159-72. [PMID: 28178675 DOI: 10.18632/oncotarget.15020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
36 Akamatsu N, Sugawara Y, Hashimoto D. Surgical strategy for bile duct cancer: Advances and current limitations. World J Clin Oncol 2011; 2(2): 94-107 [PMID: 21603318 DOI: 10.5306/wjco.v2.i2.94] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
37 Dokduang H, Jamnongkarn W, Promraksa B, Suksawat M, Padthaisong S, Thanee M, Phetcharaburanin J, Namwat N, Sangkhamanon S, Titapun A, Khuntikeo N, Klanrit P, Loilome W. In vitro and in vivo Anti-Tumor Effects of Pan-HER Inhibitor Varlitinib on Cholangiocarcinoma Cell Lines. Drug Des Devel Ther 2020;14:2319-34. [PMID: 32606601 DOI: 10.2147/DDDT.S250061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
38 Jan YY, Yeh CN, Yeh TS, Hwang TL, Chen MF. Clinicopathological factors predicting long-term overall survival after hepatectomy for peripheral cholangiocarcinoma. World J Surg 2005;29:894-8. [PMID: 15951931 DOI: 10.1007/s00268-005-7763-7] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 2.7] [Reference Citation Analysis]
39 Kurokawa H, Ito H, Matsui H. Porphylipoprotein Accumulation and Porphylipoprotein Photodynamic Therapy Effects Involving Cancer Cell-Specific Cytotoxicity. Int J Mol Sci 2021;22:7306. [PMID: 34298933 DOI: 10.3390/ijms22147306] [Reference Citation Analysis]
40 Yu JH, Zhong XY, Zhang WG, Wang ZD, Dong Q, Tai S, Li H, Cui YF. CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cells. Oncol Rep 2012;27:1266-76. [PMID: 22209942 DOI: 10.3892/or.2011.1617] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
41 Bridgewater J, Lopes A, Palmer D, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Valle J, Wasan H. Quality of life, long-term survivors and long-term outcome from the ABC-02 study. Br J Cancer 2016;114:965-71. [PMID: 27115567 DOI: 10.1038/bjc.2016.64] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
42 Yang X, Wang S, Mu Y, Zheng Y. Schisandrin B inhibits cell proliferation and induces apoptosis in human cholangiocarcinoma cells. Oncol Rep 2016;36:1799-806. [PMID: 27499090 DOI: 10.3892/or.2016.4992] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
43 Shi C, Chandrasekaran A, Thuluvath PJ, Karikari C, Argani P, Goggins M, Maitra A, Eshleman JR. Ultrasensitive detection of KRAS2 mutations in bile and serum from patients with biliary tract carcinoma using LigAmp technology. J Mol Diagn 2009;11:583-9. [PMID: 19815696 DOI: 10.2353/jmoldx.2009.090061] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
44 Yoon JH, Gores GJ. Diagnosis, Staging, and Treatment of Cholangiocarcinoma. Curr Treat Options Gastroenterol. 2003;6:105-112. [PMID: 12628069 DOI: 10.1007/s11938-003-0011-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
45 Hansel DE, Rahman A, Hidalgo M, Thuluvath PJ, Lillemoe KD, Shulick R, Ku JL, Park JG, Miyazaki K, Ashfaq R. Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol. 2003;163:217-229. [PMID: 12819026 DOI: 10.1016/s0002-9440(10)63645-0] [Cited by in Crossref: 83] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
46 Hahnvajanawong C, Boonyanugomol W, Nasomyon T, Loilome W, Namwat N, Anantachoke N, Tassaneeyakul W, Sripa B, Namwat W, Reutrakul V. Apoptotic activity of caged xanthones from Garcinia hanburyi in cholangiocarcinoma cell lines. World J Gastroenterol 2010; 16(18): 2235-2243 [PMID: 20458760 DOI: 10.3748/wjg.v16.i18.2235] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
47 Gatto M, Alvaro D. New insights on cholangiocarcinoma. World J Gastrointest Oncol 2010; 2(3): 136-145 [PMID: 21160821 DOI: 10.4251/wjgo.v2.i3.136] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
48 André T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, Clemens MR, Louvet C, Perez N, Mehmud F. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer. 2008;99:862-867. [PMID: 19238628 DOI: 10.1038/sj.bjc.6604628] [Cited by in Crossref: 116] [Cited by in F6Publishing: 147] [Article Influence: 8.9] [Reference Citation Analysis]
49 Yang XQ, Xu YF, Guo S, Liu Y, Ning SL, Lu XF, Yang H, Chen YX. Clinical significance of nerve growth factor and tropomyosin-receptor-kinase signaling pathway in intrahepatic cholangiocarcinoma. World J Gastroenterol 2014; 20(14): 4076-4084 [PMID: 24744599 DOI: 10.3748/wjg.v20.i14.4076] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
50 Kish M, Chan K, Perry K, Ko YJ. A systematic review and network meta-analysis of adjuvant therapy for curatively resected biliary tract cancers. Curr Oncol 2020;27:e20-6. [PMID: 32218664 DOI: 10.3747/co.27.5465] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
51 Won HS, Lee MA, Chung ES, Kim DG, You YK, Hong TH, Lee IS. Comparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer. BMC Cancer 2010;10:564. [PMID: 20955617 DOI: 10.1186/1471-2407-10-564] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
52 Stavrou GA, Donati M, Faiss S, Jenner RM, Niehaus KJ, Oldhafer KJ. [Perihilar cholangiocarcinoma (Klatskin tumor)]. Chirurg 2014;85:155-65; quiz 166-7. [PMID: 24464335 DOI: 10.1007/s00104-012-2390-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
53 Miyakawa S, Ishihara S, Takada T, Miyazaki M, Tsukada K, Nagino M, Kondo S, Furuse J, Saito H, Tsuyuguchi T. Flowcharts for the management of biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg. 2008;15:7-14. [PMID: 18274839 DOI: 10.1007/s00534-007-1275-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
54 Pietersen AM, Rutjes SA, van Tongeren J, Vogels R, Wesseling JG, Noteborn MH. The tumor-selective viral protein apoptin effectively kills human biliary tract cancer cells. J Mol Med (Berl) 2004;82:56-63. [PMID: 14647920 DOI: 10.1007/s00109-003-0486-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
55 Sahara K, Farooq SA, Tsilimigras DI, Merath K, Paredes AZ, Wu L, Mehta R, Hyer JM, Endo I, Pawlik TM. Immunotherapy utilization for hepatobiliary cancer in the United States: disparities among patients with different socioeconomic status. Hepatobiliary Surg Nutr 2020;9:13-24. [PMID: 32140475 DOI: 10.21037/hbsn.2019.07.01] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
56 Hsu C, Shen YC, Yang CH, Yeh KH, Lu YS, Hsu CH, Liu HT, Li CC, Chen JS, Wu CY, Cheng AL. Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract. Br J Cancer 2004;90:1715-9. [PMID: 15150619 DOI: 10.1038/sj.bjc.6601796] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
57 Gu TL, Deng X, Huang F, Tucker M, Crosby K, Rimkunas V, Wang Y, Deng G, Zhu L, Tan Z. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One. 2011;6:e15640. [PMID: 21253578 DOI: 10.1371/journal.pone.0015640] [Cited by in Crossref: 197] [Cited by in F6Publishing: 200] [Article Influence: 17.9] [Reference Citation Analysis]
58 Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007;96:896-902. [PMID: 17325704 DOI: 10.1038/sj.bjc.6603648] [Cited by in Crossref: 314] [Cited by in F6Publishing: 287] [Article Influence: 20.9] [Reference Citation Analysis]
59 van der Gaag NA, de Castro SM, Rauws EA, Bruno MJ, van Eijck CH, Kuipers EJ, Gerritsen JJ, Rutten JP, Greve JW, Hesselink EJ. Preoperative biliary drainage for periampullary tumors causing obstructive jaundice; DRainage vs. (direct) OPeration (DROP-trial). BMC Surg. 2007;7:3. [PMID: 17352805 DOI: 10.1186/1471-2482-7-3] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 3.6] [Reference Citation Analysis]
60 Pausch J, Gatzen M. [Treatment of cholestatic hepatic diseases: more than the substitution of fat soluble vitamins?]. Internist (Berl) 2006;47:1239-40, 1242-4. [PMID: 17077981 DOI: 10.1007/s00108-006-1732-6] [Reference Citation Analysis]
61 Castaldo ET, Pinson CW. Liver transplantation for non-hepatocellular carcinoma malignancy. HPB (Oxford) 2007;9:98-103. [PMID: 18333123 DOI: 10.1080/13651820601156090] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
62 Sun D, Ma J, Wang J, Han C, Qian Y, Chen G, Li X, Zhang J, Cui P, Du W, Wu Z, Chen S, Zheng X, Yue Z, Song J, Gao C, Zhao X, Cai S, Hu Y. Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer. Cancer Immunol Immunother 2019;68:1527-35. [PMID: 31535160 DOI: 10.1007/s00262-019-02386-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
63 Xu S, Zhang XJ, Guan LJ, Li B, Wang L, Li XG. Proton Pump Inhibitors Increase the Risk of Early Biliary Infection After Placement of Percutaneous Transhepatic Biliary Stents. J Vasc Interv Radiol 2021;32:569-75. [PMID: 33461872 DOI: 10.1016/j.jvir.2020.12.020] [Reference Citation Analysis]
64 Yin BB, Wu SJ, Zong HJ, Ma BJ, Cai D. Preliminary screening and identification of stem cell-like sphere clones in a gallbladder cancer cell line GBC-SD. J Zhejiang Univ Sci B. 2011;12:256-263. [PMID: 21462380 DOI: 10.1631/jzus.b1000303] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
65 Wang B, Li H, Yang R, Zhou S, Zou S. Decitabine inhibits the cell growth of cholangiocarcinoma in cultured cell lines and mouse xenografts. Oncol Lett 2014;8:1919-24. [PMID: 25295073 DOI: 10.3892/ol.2014.2499] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
66 Lee JD, Kang WJ, Yun M. Primary Cancer of the Liver and Biliary Duct. PET Clin 2008;3:169-86. [PMID: 27156461 DOI: 10.1016/j.cpet.2008.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
67 Keane MG, Horsfall L, Rait G, Pereira SP. A case-control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer. BMJ Open. 2014;4:e005720. [PMID: 25410605 DOI: 10.1136/bmjopen-2014-005720] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 5.1] [Reference Citation Analysis]
68 Ghosn M, Kourie HR, El Rassy E, Chebib R, El Karak F, Hanna C, Nasr D. Optimum chemotherapy for the management of advanced biliary tract cancer. World J Gastroenterol 2015; 21(14): 4121-4125 [PMID: 25892861 DOI: 10.3748/wjg.v21.i14.4121] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
69 Mahmud MS, May GR, Kamal MM, Khwaja AS, Sun C, Vitkin A, Yang VX. Imaging pancreatobiliary ductal system with optical coherence tomography: A review. World J Gastrointest Endosc 2013; 5(11): 540-550 [PMID: 24255746 DOI: 10.4253/wjge.v5.i11.540] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
70 Lee TY, Cheon YK, Shim CS. Current status of photodynamic therapy for bile duct cancer. Clin Endosc. 2013;46:38-44. [PMID: 23423177 DOI: 10.5946/ce.2013.46.1.38] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
71 Hayashibe A, Kameyama M. Clinical results of intra-arterial adjuvant chemotherapy for prevention of liver metastasis following curative resection of biliary tract cancer. HPB (Oxford) 2008;10:144-7. [PMID: 18773093 DOI: 10.1080/13651820701883122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
72 Hirata K, Kuwatani M, Suda G, Ishikawa M, Sugiura R, Kato S, Kawakubo K, Sakamoto N. A Novel Approach for the Genetic Analysis of Biliary Tract Cancer Specimens Obtained Through Endoscopic Ultrasound-Guided Fine Needle Aspiration Using Targeted Amplicon Sequencing. Clin Transl Gastroenterol 2019;10:e00022. [PMID: 30908307 DOI: 10.14309/ctg.0000000000000022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
73 van der Gaag NA, Kloek JJ, de Castro SM, Busch OR, van Gulik TM, Gouma DJ. Preoperative biliary drainage in patients with obstructive jaundice: history and current status. J Gastrointest Surg. 2009;13:814-820. [PMID: 18726134 DOI: 10.1007/s11605-008-0618-4] [Cited by in Crossref: 107] [Cited by in F6Publishing: 94] [Article Influence: 7.6] [Reference Citation Analysis]
74 Yang W, Sun Y. Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview. Onco Targets Ther 2021;14:1341-66. [PMID: 33658799 DOI: 10.2147/OTT.S297643] [Reference Citation Analysis]
75 Xu HX, Chen LD, Liu LN, Zhang YF, Guo LH, Liu C. Contrast-enhanced ultrasound of intrahepatic cholangiocarcinoma: correlation with pathological examination. Br J Radiol. 2012;85:1029-1037. [PMID: 22374276 DOI: 10.1259/bjr/21653786] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
76 Wu TT, Li HC, Li WM, Ao GK, Lin H, Zheng F, Song JY. Percutaneous Intraluminal Radiofrequency Ablation for Malignant Extrahepatic Biliary Obstruction: A Safe and Feasible Method. Dig Dis Sci. 2015;60:2158-2163. [PMID: 25648642 DOI: 10.1007/s10620-015-3547-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
77 Han JY, Ahn KS, Kim TS, Kim YH, Cho KB, Shin DW, Baek WK, Suh SI, Jang BC, Kang KJ. Liquid Biopsy from Bile-Circulating Tumor DNA in Patients with Biliary Tract Cancer. Cancers (Basel) 2021;13:4581. [PMID: 34572808 DOI: 10.3390/cancers13184581] [Reference Citation Analysis]
78 Bale R, Schullian P, Haidu M, Widmann G. [Stereotactic Radiofrequency Ablation (SRFA) of intrahepatic cholangiocellular carcinomas: a minimal invasive alternative to liver resection]. Wien Med Wochenschr 2013;163:128-31. [PMID: 23392811 DOI: 10.1007/s10354-013-0182-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
79 Mao ZY, Guo XC, Su D, Wang LJ, Zhang TT, Bai L. Prognostic Factors of Cholangiocarcinoma After Surgical Resection: A Retrospective Study of 293 Patients. Med Sci Monit 2015;21:2375-81. [PMID: 26269932 DOI: 10.12659/MSM.893586] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
80 Cherif S, Rais H, Hakmaoui A, Sellami S, Elantri S, Amine A. Linking Helicobacter pylori with gallbladder and biliary tract cancer in Moroccan population using clinical and pathological profiles. Bioinformation 2019;15:735-43. [PMID: 31831956 DOI: 10.6026/97320630015735] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
81 Paolicchi E, Pacetti P, Giovannetti E, Mambrini A, Orlandi M, Crea F, Romani AA, Tartarini R, Danesi R, Peters GJ, Cantore M. A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma. Oncol Lett 2013;6:1487-91. [PMID: 24179546 DOI: 10.3892/ol.2013.1559] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
82 Anderson JE, Hemming AW, Chang DC, Talamini MA, Mekeel KL. Surgical management trends for cholangiocarcinoma in the USA 1998-2009. J Gastrointest Surg 2012;16:2225-32. [PMID: 22847574 DOI: 10.1007/s11605-012-1980-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
83 Liu ZH, Ma YL, He YP, Zhang P, Zhou YK, Qin H. Tamoxifen reverses the multi-drug-resistance of an established human cholangiocarcinoma cell line in combined chemotherapeutics. Mol Biol Rep. 2011;38:1769-1775. [PMID: 20835928 DOI: 10.1007/s11033-010-0291-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
84 Belghiti J, Ogata S. Preoperative optimization of the liver for resection in patients with hilar cholangiocarcinoma. HPB (Oxford). 2005;7:252-253. [PMID: 18333201 DOI: 10.1080/13651820500372335] [Cited by in Crossref: 45] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
85 Doval DC, Sekhon JS, Gupta SK, Fuloria J, Shukla VK, Gupta S, Awasthy BS. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer 2004;90:1516-20. [PMID: 15083178 DOI: 10.1038/sj.bjc.6601736] [Cited by in Crossref: 92] [Cited by in F6Publishing: 79] [Article Influence: 5.1] [Reference Citation Analysis]
86 Wang LJ, Zhang KL, Zhang N, Ma XW, Yan SW, Cao DH, Shi SJ. Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma. Oncotarget 2015;6:18631-40. [PMID: 26087181 DOI: 10.18632/oncotarget.4072] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
87 Kim KH, Joo J, Park B, Park SJ, Lee WJ, Han SS, Kim TH, Hong EK, Woo SM, Yoo BC. Reduced levels of N'-methyl-2-pyridone-5-carboxamide and lysophosphatidylcholine 16:0 in the serum of patients with intrahepatic cholangiocarcinoma, and the correlation with recurrence-free survival. Oncotarget 2017;8:112598-609. [PMID: 29348849 DOI: 10.18632/oncotarget.22607] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
88 Figueras J, Valls C. El tratamiento quirúrgico del tumor de Klatskin. Una asignatura pendiente de la cirugía. Cirugía Española 2001;70:175-6. [DOI: 10.1016/s0009-739x(01)71872-6] [Reference Citation Analysis]
89 Chung YE, Kim MJ, Park YN, Lee YH, Choi JY. Staging of extrahepatic cholangiocarcinoma. Eur Radiol. 2008;18:2182-2195. [PMID: 18458911 DOI: 10.1007/s00330-008-1006-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
90 Li Q, Zhan M, Chen W, Zhao B, Yang K, Yang J, Yi J, Huang Q, Mohan M, Hou Z, Wang J. Phenylethyl isothiocyanate reverses cisplatin resistance in biliary tract cancer cells via glutathionylation-dependent degradation of Mcl-1. Oncotarget 2016;7:10271-82. [PMID: 26848531 DOI: 10.18632/oncotarget.7171] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
91 Letelier P, Riquelme I, Hernández AH, Guzmán N, Farías JG, Roa JC. Circulating MicroRNAs as Biomarkers in Biliary Tract Cancers. Int J Mol Sci 2016;17:E791. [PMID: 27223281 DOI: 10.3390/ijms17050791] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
92 Fornaro L, Cereda S, Aprile G, Di Girolamo S, Santini D, Silvestris N, Lonardi S, Leone F, Milella M, Vivaldi C. Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. Br J Cancer. 2014;110:2165-2169. [PMID: 24714745 DOI: 10.1038/bjc.2014.190] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 5.0] [Reference Citation Analysis]
93 Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardière C, Boucher E, Fartoux L, Faivre S, Blanc JF, Viret F. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014;15:819-828. [PMID: 24852116 DOI: 10.1016/s1470-2045(14)70212-8] [Cited by in Crossref: 220] [Cited by in F6Publishing: 120] [Article Influence: 27.5] [Reference Citation Analysis]
94 Kim H, Heo MH, Kim JY. Comparison of the effects of adjuvant concurrent chemoradiotherapy and chemotherapy for resected biliary tract cancer. BMC Gastroenterol 2020;20:20. [PMID: 31992208 DOI: 10.1186/s12876-020-1171-1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
95 Kim MH, Lee SS, Lee SK, Lee SG, Suh CW, Gong GY, Park JS, Kim YH, Kim SH. Interleukin-2 gene-encoded stromal cells inhibit the growth of metastatic cholangiocarcinomas. World J Gastroenterol 2006; 12(12): 1889-1894 [PMID: 16609995 DOI: 10.3748/wjg.v12.i12.1889] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
96 Mott JL, Bronk SF, Mesa RA, Kaufmann SH, Gores GJ. BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. Mol Cancer Ther 2008;7:2339-47. [PMID: 18723481 DOI: 10.1158/1535-7163.MCT-08-0285] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
97 Park JK, Yoon YB, Kim YT, Ryu JK, Yoon WJ, Lee SH, Yu SJ, Kang HY, Lee JY, Park MJ. Management strategies for gallbladder polyps: is it possible to predict malignant gallbladder polyps? Gut Liver 2008;2:88-94. [PMID: 20485616 DOI: 10.5009/gnl.2008.2.2.88] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
98 Tang HH, Chang S, Wang XW, Huang Y, Gong XJ, Zhou J. Diagnostic and surgical therapeutic features of extrahepatic bile duct carcinoma without jaundice. World J Gastroenterol 2004; 10(20): 3060-3061 [PMID: 15378794 DOI: 10.3748/wjg.v10.i20.3060] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
99 Lim JH, Ryu JK, Choi YJ, Kwon J, Kim JY, Lee YB, Kim JH, Yoon WJ, Kim YT, Yoon YB. A Case of Common Bile Duct Cancer That Completely Responded to Combination Chemotherapy of Gemcitabine and TS-1. Gut Liver. 2013;7:371-376. [PMID: 23710321 DOI: 10.5009/gnl.2013.7.3.371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
100 Ke X, Jin B, You W, Chen Y, Xu H, Zhao H, Lu X, Sang X, Zhong S, Yang H, Mao Y, Du S. Comprehensive analysis of coagulation indices for predicting survival in patients with biliary tract cancer. BMC Cancer 2021;21:953. [PMID: 34433454 DOI: 10.1186/s12885-021-08684-w] [Reference Citation Analysis]
101 Zhai N, Liu J, Xu P, Liu B, Fan Y, Lv C. Pulmonary metastasis of distal cholangiocarcinoma with multiple cavities in bilateral lungs: A case report. Thorac Cancer 2020;11:2998-3000. [PMID: 32885606 DOI: 10.1111/1759-7714.13584] [Reference Citation Analysis]
102 Zhao X, Zhang C, Zhou H, Xiao B, Cheng Y, Wang J, Yao F, Duan C, Chen R, Liu Y, Feng C, Li H, Li J, Dai R. Synergistic antitumor activity of the combination of salubrinal and rapamycin against human cholangiocarcinoma cells. Oncotarget 2016;7:85492-501. [PMID: 27863431 DOI: 10.18632/oncotarget.13408] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
103 Liu Z, Alsaggaf R, McGlynn KA, Anderson LA, Tsai HT, Zhu B, Zhu Y, Mbulaiteye SM, Gadalla SM, Koshiol J. Statin use and reduced risk of biliary tract cancers in the UK Clinical Practice Research Datalink. Gut 2019;68:1458-64. [PMID: 30448774 DOI: 10.1136/gutjnl-2018-317504] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
104 Su WC, Shiesh SC, Liu HS, Chen CY, Chow NH, Lin XZ. Expression of oncogene products HER2/Neu and Ras and fibrosis-related growth factors bFGF, TGF-beta, and PDGF in bile from biliary malignancies and inflammatory disorders. Dig Dis Sci. 2001;46:1387-1392. [PMID: 11478488 DOI: 10.1023/a:1010619316436] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
105 Yusoff AR, Abdul Razak MM, Yoong BK, Vijeyasingam R, Siti ZM. Survival analysis of cholangiocarcinoma: A 10-year experience in Malaysia. World J Gastroenterol 2012; 18(5): 458-465 [PMID: 22346252 DOI: 10.3748/wjg.v18.i5.458] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
106 Marubashi S, Gotoh K, Takahashi H, Ohigashi H, Yano M, Ishikawa O, Sakon M. Prediction of the postoperative prognosis of intrahepatic cholangiocarcinoma (ICC): importance of preoperatively- determined anatomic invasion level and number of tumors. Dig Dis Sci 2014;59:201-13. [PMID: 24122559 DOI: 10.1007/s10620-013-2894-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
107 Chapman MH, Pereira SP. Cholangiocarcinoma: improving biliary drainage with PDT. Photodiagnosis Photodyn Ther 2009;6:82-3. [PMID: 19683206 DOI: 10.1016/j.pdpdt.2009.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
108 Xiong J, Lin J, Wang A, Wang Y, Zheng Y, Sang X, Xu Y, Lu X, Zhao H. Tea consumption and the risk of biliary tract cancer: a systematic review and dose-response meta-analysis of observational studies. Oncotarget 2017;8:39649-57. [PMID: 28454105 DOI: 10.18632/oncotarget.16963] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
109 Dai K, Quan J, Yan F, Jin X, Pan X, Song X, Zhang S, Ren Q, Liu J, Liu X. lncRNAs as potential molecular biomarkers in the clinicopathology and prognosis of cholangiocarcinoma: a systematic review and meta-analysis. Onco Targets Ther 2019;12:1905-15. [PMID: 30881042 DOI: 10.2147/OTT.S188134] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
110 Mayr C, Wagner A, Loeffelberger M, Bruckner D, Jakab M, Berr F, Di Fazio P, Ocker M, Neureiter D, Pichler M. The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells. Oncotarget. 2016;7:745-758. [PMID: 26623561 DOI: 10.18632/oncotarget.6378] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
111 Hass HG, Nehls O, Jobst J, Frilling A, Vogel U, Kaiser S. Identification of osteopontin as the most consistently over-expressed gene in intrahepatic cholangiocarcinoma: Detection by oligonucleotide microarray and real-time PCR analysis. World J Gastroenterol 2008; 14(16): 2501-2510 [PMID: 18442196 DOI: 10.3748/wjg.14.2501] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
112 Höpfner M, Schuppan D, Scherübl H. Targeted medical therapy of biliary tract cancer: Recent advances and future perspectives. World J Gastroenterol 2008; 14(46): 7021-7032 [PMID: 19084910 DOI: 10.3748/wjg.14.7021] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
113 Chen Y, Li H, Jiang X, Chen D, Ni J, Sun H, Luo J, Yao H, Xu L. Regional thermochemotherapy versus hepatic arterial infusion chemotherapy for palliative treatment of advanced hilar cholangiocarcinoma: a retrospective controlled study.Eur Radiol. 2016;26:3500-3509. [PMID: 26822373 DOI: 10.1007/s00330-016-4208-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
114 Sripa B, Leungwattanawanit S, Nitta T, Wongkham C, Bhudhisawasdi V, Puapairoj A, Sripa C, Miwa M. Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100). World J Gastroenterol 2005; 11(22): 3392-3397 [PMID: 15948244 DOI: 10.3748/wjg.v11.i22.3392] [Cited by in CrossRef: 106] [Cited by in F6Publishing: 110] [Article Influence: 6.2] [Reference Citation Analysis]
115 Yeh CN, Lin KJ, Chen TW, Wu RC, Tsao LC, Chen YT, Weng WH, Chen MF. Characterization of a novel rat cholangiocarcinoma cell culture model-CGCCA. World J Gastroenterol 2011; 17(24): 2924-2932 [PMID: 21734803 DOI: 10.3748/wjg.v17.i24.2924] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
116 Yang HJ, Kim JH, Chun JY, Kim SJ, Lee SH, Kim H, Hwang JH. A case of adenocarcinoma in situ of the distal common bile duct diagnosed by percutaneous transhepatic cholangioscopy. Korean J Intern Med 2012;27:211-5. [PMID: 22707894 DOI: 10.3904/kjim.2012.27.2.211] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
117 Kim ST, Oh SY, Lee J, Kang JH, Lee HW, Lee MA, Sohn BS, Hong JH, Park YS, Park JO, Lim HY. Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial. J Cancer 2019;10:6185-90. [PMID: 31772650 DOI: 10.7150/jca.37610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
118 Mansour JC, Aloia TA, Crane CH, Heimbach JK, Nagino M, Vauthey JN. Hilar cholangiocarcinoma: expert consensus statement. HPB (Oxford). 2015;17:691-699. [PMID: 26172136 DOI: 10.1111/hpb.12450] [Cited by in Crossref: 169] [Cited by in F6Publishing: 190] [Article Influence: 28.2] [Reference Citation Analysis]
119 Wadsworth CA, Dixon PH, Wong JH, Chapman MH, McKay SC, Sharif A, Spalding DR, Pereira SP, Thomas HC, Taylor-Robinson SD, Whittaker J, Williamson C, Khan SA. Genetic factors in the pathogenesis of cholangiocarcinoma. Dig Dis 2011;29:93-7. [PMID: 21691113 DOI: 10.1159/000324688] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
120 Tsukada K, Takada T, Miyazaki M, Miyakawa S, Nagino M, Kondo S, Furuse J, Saito H, Tsuyuguchi T, Kimura F. Diagnosis of biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg. 2008;15:31-40. [PMID: 18274842 DOI: 10.1007/s00534-007-1278-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
121 Gupta M, Pai RR, Dileep D, Gopal S, Shenoy S. Role of biliary tract cytology in the evaluation of extrahepatic cholestatic jaundice. J Cytol 2013;30:162-8. [PMID: 24130407 DOI: 10.4103/0970-9371.117657] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
122 Nelson SM, Gao YT, Nogueira LM, Shen MC, Wang B, Rashid A, Hsing AW, Koshiol J. Diet and biliary tract cancer risk in Shanghai, China. PLoS One 2017;12:e0173935. [PMID: 28288186 DOI: 10.1371/journal.pone.0173935] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
123 Harder J, Riecken B, Kummer O, Lohrmann C, Otto F, Usadel H, Geissler M, Opitz O, Henss H. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer 2006;95:848-52. [PMID: 16969352 DOI: 10.1038/sj.bjc.6603334] [Cited by in Crossref: 85] [Cited by in F6Publishing: 79] [Article Influence: 5.3] [Reference Citation Analysis]
124 Chen X, Chen J, Liu X, Guo Z, Sun X, Zhang J. The real-time dynamic monitoring of microRNA function in cholangiocarcinoma. PLoS One 2014;9:e99431. [PMID: 24918778 DOI: 10.1371/journal.pone.0099431] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
125 Wang H, Zhan M, Xu SW, Chen W, Long MM, Shi YH, Liu Q, Mohan M, Wang J. miR-218-5p restores sensitivity to gemcitabine through PRKCE/MDR1 axis in gallbladder cancer. Cell Death Dis 2017;8:e2770. [PMID: 28492560 DOI: 10.1038/cddis.2017.178] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
126 Yang JD, Kim B, Sanderson SO, Sauver JS, Yawn BP, Larson JJ, Therneau TM, Roberts LR, Gores GJ, Kim WR. Biliary tract cancers in Olmsted County, Minnesota, 1976-2008. Am J Gastroenterol. 2012;107:1256-1262. [PMID: 22751468 DOI: 10.1038/ajg.2012.173] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 4.9] [Reference Citation Analysis]
127 Zhang WJ, Xu GF, Zou XP, Wang WB, Yu JC, Wu GZ, Lu CL. Incidental gallbladder carcinoma diagnosed during or after laparoscopic cholecystectomy. World J Surg. 2009;33:2651-2656. [PMID: 19760311 DOI: 10.1007/s00268-009-0218-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
128 Cereda S, Belli C, Reni M. Adjuvant treatment in biliary tract cancer: To treat or not to treat? World J Gastroenterol 2012; 18(21): 2591-2596 [PMID: 22690066 DOI: 10.3748/wjg.v18.i21.2591] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
129 Currie BM, Soulen MC. Decision Making: Intra-arterial Therapies for Cholangiocarcinoma-TACE and TARE. Semin Intervent Radiol 2017;34:92-100. [PMID: 28579676 DOI: 10.1055/s-0037-1602591] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
130 Cho KM, Oh DY, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Bang YJ. Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications. Oncologist 2015;20:926-33. [PMID: 26099746 DOI: 10.1634/theoncologist.2014-0356] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
131 Richter JA, Kahaleh M. Photodynamic therapy: Palliation and endoscopic technique in cholangiocarcinoma. World J Gastrointest Endosc 2010; 2(11): 357-361 [PMID: 21173912 DOI: 10.4253/wjge.v2.i11.357] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
132 Cheng CT, Chu YY, Yeh CN, Huang SC, Chen MH, Wang SY, Tsai CY, Chiang KC, Chen YY, Ma MC, Liu CT, Chen TW, Yeh TS. Peritumoral SPARC expression and patient outcome with resectable intrahepatic cholangiocarcinoma. Onco Targets Ther 2015;8:1899-907. [PMID: 26251613 DOI: 10.2147/OTT.S78728] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
133 Charbel H, Al-Kawas FH. Cholangiocarcinoma treatment. Curr Gastroenterol Rep 2012;14:528-33. [PMID: 22968375 DOI: 10.1007/s11894-012-0286-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
134 Yoo KH, Kim NK, Kwon WI, Lee C, Kim SY, Jang J, Ahn J, Kang M, Jang H, Kim ST, Ahn S, Jang KT, Park YS, Park WY, Lee J, Heo JS, Park JO. Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing. Transl Oncol 2016;9:173-8. [PMID: 27267833 DOI: 10.1016/j.tranon.2016.01.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
135 Lang H, Sotiropoulos GC, Frühauf NR, Dömland M, Paul A, Kind EM, Malagó M, Broelsch CE. Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg 2005;241:134-43. [PMID: 15622001 DOI: 10.1097/01.sla.0000149426.08580.a1] [Cited by in Crossref: 143] [Cited by in F6Publishing: 117] [Article Influence: 8.4] [Reference Citation Analysis]
136 Fingas CD, Bronk SF, Werneburg NW, Mott JL, Guicciardi ME, Cazanave SC, Mertens JC, Sirica AE, Gores GJ. Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. Hepatology. 2011;54:2076-2088. [PMID: 22038837 DOI: 10.1002/hep.24588] [Cited by in Crossref: 102] [Cited by in F6Publishing: 144] [Article Influence: 10.2] [Reference Citation Analysis]
137 Huang QX, Cui JY, Ma H, Jia XM, Huang FL, Jiang LX. Screening of potential biomarkers for cholangiocarcinoma by integrated analysis of microarray data sets. Cancer Gene Ther 2016;23:48-53. [PMID: 26679756 DOI: 10.1038/cgt.2015.66] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
138 Bluethner T, Niederhagen M, Caca K, Serr F, Witzigmann H, Moebius C, Mossner J, Wiedmann M. Inhibition of histone deacetylase for the treatment of biliary tract cancer: A new effective pharmacological approach. World J Gastroenterol 2007; 13(35): 4761-4770 [PMID: 17729398 DOI: 10.3748/wjg.v13.i35.4761] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
139 Verslype C, Prenen H, Van Cutsem E. The role of chemotherapy in biliary tract carcinoma. HPB (Oxford) 2008;10:164-7. [PMID: 18773046 DOI: 10.1080/13651820802029427] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
140 Tomizawa Y, Tian J. Photodynamic therapy for unresectable cholangiocarcinoma. Dig Dis Sci. 2012;57:274-283. [PMID: 22057285 DOI: 10.1007/s10620-011-1957-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
141 Ulahannan SV, Rahma OE, Duffy AG, Makarova-Rusher OV, Kurtoglu M, Liewehr DJ, Steinberg SM, Greten TF. Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades. Hepat Oncol 2015;2:39-50. [PMID: 25685318 DOI: 10.2217/hep.14.36] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
142 Abeysinghe V, Sundararajan S, Delriviere L, Tibballs J. Selective internal radiation therapy (SIRT) with yttrium-90 microspheres for unresectable intrahepatic cholangiocarcinoma. BMJ Case Rep 2018;2018:bcr-2017-223539. [PMID: 29523614 DOI: 10.1136/bcr-2017-223539] [Reference Citation Analysis]
143 Zhang K, Zhang B, Lu Y, Sun C, Zhao W, Jiao X, Hu J, Mu P, Lu H, Zhou C. Slug inhibition upregulates radiation-induced PUMA activity leading to apoptosis in cholangiocarcinomas. Med Oncol 2011;28 Suppl 1:S301-9. [PMID: 21120639 DOI: 10.1007/s12032-010-9759-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
144 Fedirko V, Lukanova A, Bamia C, Trichopolou A, Trepo E, Nöthlings U, Schlesinger S, Aleksandrova K, Boffetta P, Tjønneland A, Johnsen NF, Overvad K, Fagherazzi G, Racine A, Boutron-Ruault MC, Grote V, Kaaks R, Boeing H, Naska A, Adarakis G, Valanou E, Palli D, Sieri S, Tumino R, Vineis P, Panico S, Bueno-de-Mesquita HBA, Siersema PD, Peeters PH, Weiderpass E, Skeie G, Engeset D, Quirós JR, Zamora-Ros R, Sánchez MJ, Amiano P, Huerta JM, Barricarte A, Johansen D, Lindkvist B, Sund M, Werner M, Crowe F, Khaw KT, Ferrari P, Romieu I, Chuang SC, Riboli E, Jenab M. Glycemic index, glycemic load, dietary carbohydrate, and dietary fiber intake and risk of liver and biliary tract cancers in Western Europeans. Ann Oncol 2013;24:543-53. [PMID: 23123507 DOI: 10.1093/annonc/mds434] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 6.7] [Reference Citation Analysis]
145 Romiti A, D’Antonio C, Zullo A, Sarcina I, Di Rocco R, Barucca V, Durante V, Marchetti P. Chemotherapy for the biliary tract cancers: moving toward improved survival time. J Gastrointest Cancer. 2012;43:396-404. [PMID: 22328060 DOI: 10.1007/s12029-012-9369-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
146 Sandanayake NS, Sinclair J, Andreola F, Chapman MH, Xue A, Webster GJ, Clarkson A, Gill A, Norton ID, Smith RC, Timms JF, Pereira SP. A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures. Br J Cancer 2011;105:1370-8. [PMID: 21970875 DOI: 10.1038/bjc.2011.376] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 4.2] [Reference Citation Analysis]
147 Tariq NU, McNamara MG, Valle JW. Biliary tract cancers: current knowledge, clinical candidates and future challenges. Cancer Manag Res 2019;11:2623-42. [PMID: 31015767 DOI: 10.2147/CMAR.S157092] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
148 Gupta R, Anand A, Kumar M, Bhatt M, Singh S, Sonkar AA. Safety and Efficacy of Low-Dose Single-Agent Capecitabine in Inoperable Gallbladder Cancer with Jaundice Post-Single-System Single-Catheter External Biliary Drainage: a Pilot Study from a Highly Endemic Area. Indian J Surg Oncol 2018;9:530-7. [PMID: 30538384 DOI: 10.1007/s13193-018-0798-7] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
149 Kim KW, Kwon HC, Kim SH, Oh SY, Lee S, Lee JH, Roh MH, Kim MC, Kim KH, Kim YH, Roh YH, Jeong JS, Kim HJ. Prognostic significance of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in biliary tract cancer patients receiving adjuvant 5-fluorouracil-based chemotherapy. Mol Clin Oncol 2013;1:987-94. [PMID: 24649282 DOI: 10.3892/mco.2013.166] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
150 Wagner A, Mayr C, Bach D, Illig R, Plaetzer K, Berr F, Pichler M, Neureiter D, Kiesslich T. MicroRNAs associated with the efficacy of photodynamic therapy in biliary tract cancer cell lines. Int J Mol Sci 2014;15:20134-57. [PMID: 25380521 DOI: 10.3390/ijms151120134] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
151 Lin G, Lin KJ, Wang F, Chen TC, Yen TC, Yeh TS. Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity. Dis Model Mech 2018;11:dmm033050. [PMID: 29666220 DOI: 10.1242/dmm.033050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
152 Noel MS, Hezel AF. New and emerging treatment options for biliary tract cancer. Onco Targets Ther 2013;6:1545-52. [PMID: 24204165 DOI: 10.2147/OTT.S32545] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.1] [Reference Citation Analysis]
153 Harder J, Müller MJ, Fuchs M, Gumpp V, Schmitt-Graeff A, Fischer R, Frank M, Opitz O, Hasskarl J. Inhibitor of differentiation proteins do not influence prognosis of biliary tract cancer. World J Gastroenterol 2013; 19(48): 9334-9342 [PMID: 24409060 DOI: 10.3748/wjg.v19.i48.9334] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
154 Xu Y, Steckle S, Lui A, Dixon E, Ball CG, Sutherland FR, Spratlin J, Bathe OF. Effect of proximity to specialty care on outcomes for biliary cancers: a population-based retrospective cohort study. CMAJ Open 2019;7:E131-9. [PMID: 30819693 DOI: 10.9778/cmajo.20180082] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
155 Tsukagoshi M, Wada S, Yokobori T, Altan B, Ishii N, Watanabe A, Kubo N, Saito F, Araki K, Suzuki H, Hosouchi Y, Kuwano H. Overexpression of natural killer group 2 member D ligands predicts favorable prognosis in cholangiocarcinoma. Cancer Sci. 2016;107:116-122. [PMID: 26608587 DOI: 10.1111/cas.12853] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
156 Lee SW, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI. Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma. J Gastroenterol. 2010;45:560-566. [PMID: 20035356 DOI: 10.1007/s00535-009-0188-6] [Cited by in Crossref: 80] [Cited by in F6Publishing: 65] [Article Influence: 6.2] [Reference Citation Analysis]
157 Boberg KM, Schrumpf E. Diagnosis and treatment of cholangiocarcinoma. Curr Gastroenterol Rep 2004;6:52-9. [PMID: 14720454 DOI: 10.1007/s11894-004-0026-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
158 Jiang BG, Ge RL, Sun LL, Zong M, Wei GT, Zhang YJ. Clinical parameters predicting survival duration after hepatectomy for intrahepatic cholangiocarcinoma. Can J Gastroenterol 2011;25:603-8. [PMID: 22059167 DOI: 10.1155/2011/917097] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
159 Liu ZH, He YP, Zhou Y, Zhang P, Qin H. Establishment and identification of the human multi-drug-resistant cholangiocarcinoma cell line QBC939/ADM. Mol Biol Rep. 2011;38:3075-3082. [PMID: 20111907 DOI: 10.1007/s11033-010-9975-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
160 Chen WY, Kong CL, Meng MM, Chen WQ, Zheng LY, Mao JT, Fang SJ, Chen L, Shu GF, Yang Y, Weng QY, Chen MJ, Xu M, Ji JS. Percutaneous biliary stent combined with brachytherapy using 125I seeds for treatment of unresectable malignant obstructive jaundice: A meta-analysis. World J Clin Cases 2021; 9(35): 10979-10993 [DOI: 10.12998/wjcc.v9.i35.10979] [Reference Citation Analysis]
161 Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008;48:308-21. [PMID: 18536057 DOI: 10.1002/hep.22310] [Cited by in Crossref: 470] [Cited by in F6Publishing: 444] [Article Influence: 33.6] [Reference Citation Analysis]
162 Nakagawa R, Hiep NC, Ouchi H, Sato Y, Harada K. Expression of fatty-acid-binding protein 5 in intrahepatic and extrahepatic cholangiocarcinoma: the possibility of different energy metabolisms in anatomical location. Med Mol Morphol 2020;53:42-9. [PMID: 31432248 DOI: 10.1007/s00795-019-00230-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
163 Feisthammel J, Mössner J, Hoffmeister A. Palliative Endoscopic Treatment Options in Malignancies of the Biliopancreatic System. Viszeralmedizin 2014;30:238-43. [PMID: 26288596 DOI: 10.1159/000366145] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
164 Cho KM, Park H, Oh DY, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Bang YJ. Skeletal muscle depletion predicts survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy. Oncotarget 2017;8:79441-52. [PMID: 29108323 DOI: 10.18632/oncotarget.18345] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
165 Xiao J, Wang L, Hong T, Li B, Liu W, Qu Q, Zheng C, He X. The Prognostic Value of the CA19-9/TBIL Ratio in Patients with Biliary Tract Cancers (BTCs): A Retrospective Study. J Oncol 2021;2021:5829893. [PMID: 33688345 DOI: 10.1155/2021/5829893] [Reference Citation Analysis]
166 Pereira SP, Aithal GP, Ragunath K, Devlin J, Owen F, Meadows H. Safety and long term efficacy of porfimer sodium photodynamic therapy in locally advanced biliary tract carcinoma. Photodiagnosis Photodyn Ther. 2012;9:287-292. [PMID: 23200007 DOI: 10.1016/j.pdpdt.2012.03.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
167 Park HS, Park JS, Chun YJ, Roh YH, Moon J, Chon HJ, Choi HJ, Park JS, Lee DK, Lee SJ, Yoon DS, Jeung HC. Prognostic Factors and Scoring Model for Survival in Metastatic Biliary Tract Cancer. Cancer Res Treat 2017;49:1127-39. [PMID: 28161931 DOI: 10.4143/crt.2016.538] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
168 Yoon J, Kang SY, Lee KH, Cheon GJ, Oh DY. Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer. Cancer Res Treat 2021;53:471-9. [PMID: 33091966 DOI: 10.4143/crt.2020.577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
169 Kiesslich T, Mayr C, Wachter J, Bach D, Fuereder J, Wagner A, Alinger B, Pichler M, Di Fazio P, Ocker M. Activated hedgehog pathway is a potential target for pharmacological intervention in biliary tract cancer. Mol Cell Biochem. 2014;396:257-268. [PMID: 25064451 DOI: 10.1007/s11010-014-2161-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
170 Atanasov G, Hau HM, Dietel C, Benzing C, Krenzien F, Brandl A, Wiltberger G, Matia I, Prager I, Schierle K. Prognostic significance of macrophage invasion in hilar cholangiocarcinoma. BMC Cancer. 2015;15:790. [PMID: 26497197 DOI: 10.1186/s12885-015-1795-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
171 Johnson C, Han Y, Hughart N, McCarra J, Alpini G, Meng F. Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer 2012;1:58-70. [PMID: 22724089 DOI: 10.3978/j.issn.2224-4778.2011.11.02] [Cited by in F6Publishing: 61] [Reference Citation Analysis]
172 Shigehara K, Yokomuro S, Ishibashi O, Mizuguchi Y, Arima Y, Kawahigashi Y, Kanda T, Akagi I, Tajiri T, Yoshida H, Takizawa T, Uchida E. Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer. PLoS One. 2011;6:e23584. [PMID: 21858175 DOI: 10.1371/journal.pone.0023584] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 8.5] [Reference Citation Analysis]
173 Dokduang H, Juntana S, Techasen A, Namwat N, Yongvanit P, Khuntikeo N, Riggins GJ, Loilome W. Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment. Tumour Biol 2013;34:3519-28. [PMID: 23812726 DOI: 10.1007/s13277-013-0930-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
174 Mayr C, Wagner A, Neureiter D, Pichler M, Jakab M, Illig R, Berr F, Kiesslich T. The green tea catechin epigallocatechin gallate induces cell cycle arrest and shows potential synergism with cisplatin in biliary tract cancer cells. BMC Complement Altern Med 2015;15:194. [PMID: 26100134 DOI: 10.1186/s12906-015-0721-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 5.1] [Reference Citation Analysis]
175 Feng C, He K, Zhang C, Su S, Li B, Li Y, Duan CY, Chen S, Chen R, Liu Y, Li H, Wei M, Xia X, Dai R. JNK contributes to the tumorigenic potential of human cholangiocarcinoma cells through the mTOR pathway regulated GRP78 induction. PLoS One 2014;9:e90388. [PMID: 24587347 DOI: 10.1371/journal.pone.0090388] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
176 Ramírez-Merino N, Aix SP, Cortés-Funes H. Chemotherapy for cholangiocarcinoma: An update. World J Gastrointest Oncol 2013; 5(7): 171-176 [PMID: 23919111 DOI: 10.4251/wjgo.v5.i7.171] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 82] [Article Influence: 7.7] [Reference Citation Analysis]
177 Selaru FM, Olaru AV, Kan T, David S, Cheng Y, Mori Y, Yang J, Paun B, Jin Z, Agarwal R, Hamilton JP, Abraham J, Georgiades C, Alvarez H, Vivekanandan P, Yu W, Maitra A, Torbenson M, Thuluvath PJ, Gores GJ, LaRusso NF, Hruban R, Meltzer SJ. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology. 2009;49:1595-1601. [PMID: 19296468 DOI: 10.1002/hep.22838] [Cited by in Crossref: 189] [Cited by in F6Publishing: 188] [Article Influence: 14.5] [Reference Citation Analysis]
178 Schrumpf E, Boberg KM. Hepatic and extrahepatic malignancies and primary sclerosing cholangitis. Gut. 2003;52:165. [PMID: 12524391 DOI: 10.1136/gut.52.2.165] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
179 von Delius S, Lersch C, Schulte-Frohlinde E, Mayr M, Schmid RM, Eckel F. Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. BMC Cancer 2005;5:61. [PMID: 15949047 DOI: 10.1186/1471-2407-5-61] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
180 Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. 2002;51 Suppl 6:VI1-VI9. [PMID: 12376491 DOI: 10.1136/gut.51.suppl_6.vi1] [Cited by in Crossref: 223] [Cited by in F6Publishing: 269] [Article Influence: 11.2] [Reference Citation Analysis]
181 Saifuku Y, Yamagata M, Koike T, Hitomi G, Kanke K, Watanabe H, Murohisa T, Tamano M, Iijima M, Kubota K, Hiraishi H. Endoscopic ultrasonography can diagnose distal biliary strictures without a mass on computed tomography. World J Gastroenterol 2010; 16(2): 237-244 [PMID: 20066744 DOI: 10.3748/wjg.v16.i2.237] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
182 Gong J, Cho M, Fakih M. Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function. J Gastrointest Oncol 2017;8:314-23. [PMID: 28480070 DOI: 10.21037/jgo.2016.09.17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
183 Lin L, Guo L, Zhang W, Cai X, Chen D, Wan X. Novel Silicone-Coated 125I Seeds for the Treatment of Extrahepatic Cholangiocarcinoma. PLoS One 2016;11:e0147701. [PMID: 26840346 DOI: 10.1371/journal.pone.0147701] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
184 Lindor KD, Kowdley KV, Harrison ME; American College of Gastroenterology. ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol. 2015;110:646-59; quiz 660. [PMID: 25869391 DOI: 10.1038/ajg.2015.112] [Cited by in Crossref: 254] [Cited by in F6Publishing: 224] [Article Influence: 36.3] [Reference Citation Analysis]
185 Yeh CN, Lin KJ, Hsiao IT, Yen TC, Chen TW, Jan YY, Chung YH, Lin CF, Chen MF. Animal PET for thioacetamide-induced rat cholangiocarcinoma: a novel and reliable platform. Mol Imaging Biol 2008;10:209-16. [PMID: 18491193 DOI: 10.1007/s11307-008-0141-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
186 Seyama Y, Makuuchi M. Current surgical treatment for bile duct cancer. World J Gastroenterol 2007; 13(10): 1505-1515 [PMID: 17461441 DOI: 10.3748/wjg.v13.i10.1505] [Cited by in CrossRef: 84] [Cited by in F6Publishing: 70] [Article Influence: 5.6] [Reference Citation Analysis]
187 Jan YY, Yeh CN, Yeh TS, Chen TC. Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: Two decades of experience at Chang Gung Memorial Hospital. World J Gastroenterol 2005; 11(12): 1779-1784 [PMID: 15793863 DOI: 10.3748/wjg.v11.i12.1779] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 36] [Article Influence: 2.5] [Reference Citation Analysis]
188 Ebata T, Nagino M, Nishio H, Igami T, Yokoyama Y, Nimura Y. Pancreatic and duodenal invasion in distal bile duct cancer: paradox in the tumor classification of the American Joint Committee on Cancer. World J Surg 2007;31:2008-15. [PMID: 17661132 DOI: 10.1007/s00268-007-9173-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
189 Shin HR, Oh JK, Lim MK, Shin A, Kong HJ, Jung KW, Won YJ, Park S, Park SJ, Hong ST. Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea. J Korean Med Sci. 2010;25:1011-1016. [PMID: 20592891 DOI: 10.3346/jkms.2010.25.7.1011] [Cited by in Crossref: 74] [Cited by in F6Publishing: 60] [Article Influence: 6.2] [Reference Citation Analysis]
190 Basu N, Skinner HG, Litzelman K, Vanderboom R, Baichoo E, Boardman LA. Telomeres and telomere dynamics: relevance to cancers of the GI tract. Expert Rev Gastroenterol Hepatol 2013;7:733-48. [PMID: 24161135 DOI: 10.1586/17474124.2013.848790] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
191 Thomas CR Jr, Merrick HW 3rd. Intraoperative radiation therapy in the multimodality approach to hepatobiliary tract cancer. Surg Oncol Clin N Am 2003;12:979-92. [PMID: 14989128 DOI: 10.1016/s1055-3207(03)00085-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
192 Gavriilidis P, Askari A, Roberts KJ, Sutcliffe RP. Appraisal of the current guidelines for management of cholangiocarcinoma-using the Appraisal of Guidelines Research and Evaluation II (AGREE II) Instrument. Hepatobiliary Surg Nutr 2020;9:126-35. [PMID: 32355672 DOI: 10.21037/hbsn.2019.09.06] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
193 Urbas R, Mayr C, Klieser E, Fuereder J, Bach D, Stättner S, Primavesi F, Jaeger T, Stanzer S, Ress AL, Löffelberger M, Wagner A, Berr F, Ritter M, Pichler M, Neureiter D, Kiesslich T. Relevance of MicroRNA200 Family and MicroRNA205 for Epithelial to Mesenchymal Transition and Clinical Outcome in Biliary Tract Cancer Patients. Int J Mol Sci 2016;17:E2053. [PMID: 27941621 DOI: 10.3390/ijms17122053] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
194 Zaydfudim VM, Wang AY, de Lange EE, Zhao Z, Moskaluk CA, Bauer TW, Adams RB. IgG4-Associated Cholangitis Can Mimic Hilar Cholangiocarcinoma. Gut Liver 2015;9:556-60. [PMID: 26033685 DOI: 10.5009/gnl14241] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
195 Fingas CD, Mertens JC, Razumilava N, Bronk SF, Sirica AE, Gores GJ. Targeting PDGFR-β in Cholangiocarcinoma. Liver Int. 2012;32:400-409. [PMID: 22133064 DOI: 10.1111/j.1478-3231.2011.02687.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 17] [Article Influence: 0.3] [Reference Citation Analysis]
196 Francis H, Alpini G, DeMorrow S. Recent advances in the regulation of cholangiocarcinoma growth. Am J Physiol Gastrointest Liver Physiol 2010;299:G1-9. [PMID: 20430870 DOI: 10.1152/ajpgi.00114.2010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 64] [Article Influence: 1.6] [Reference Citation Analysis]
197 D'Andrea MR, Gill CM, Umphlett M, Tsankova NM, Fowkes M, Bederson JB, Brastianos PK, Shrivastava RK. Brain Metastases from Biliary Tract Cancers: A Case Series and Review of the Literature in the Genomic Era. Oncologist 2020;25:447-53. [PMID: 31694894 DOI: 10.1634/theoncologist.2019-0306] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
198 Wang LJ, He CC, Sui X, Cai MJ, Zhou CY, Ma JL, Wu L, Wang H, Han SX, Zhu Q. MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN. Oncotarget. 2015;6:5932-5946. [PMID: 25803229 DOI: 10.18632/oncotarget.3465] [Cited by in Crossref: 65] [Cited by in F6Publishing: 70] [Article Influence: 10.8] [Reference Citation Analysis]
199 Uchiyama S, Chijiiwa K, Hiyoshi M, Ohuchida J, Kai M, Nagano M, Nagaike K, Kondo K, Akiyama Y, Kataoka H. Unusual segmental stricture of the lower common bile duct mimicking bile duct cancer. J Gastrointest Surg 2008;12:199-201. [PMID: 17623262 DOI: 10.1007/s11605-007-0220-1] [Reference Citation Analysis]
200 Chujan S, Suriyo T, Ungtrakul T, Pomyen Y, Satayavivad J. Potential candidate treatment agents for targeting of cholangiocarcinoma identified by gene expression profile analysis. Biomed Rep 2018;9:42-52. [PMID: 29930804 DOI: 10.3892/br.2018.1101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
201 Di Mitri R, Mocciaro F. Y-shaped bilateral self-expandable metallic stent placement for malignant hilar biliary obstruction: data from a referral center for palliative care. Scientific World Journal. 2014;2014:151502. [PMID: 24790548 DOI: 10.1155/2014/151502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
202 Brass V, Kuhlmann JB, Blum HE. Current state of nonsurgical therapies for cholangiocarcinoma. Hepat Oncol 2014;1:135-42. [PMID: 30190947 DOI: 10.2217/hep.13.9] [Reference Citation Analysis]
203 Yu J, Mahipal A, Kim R. Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib. Onco Targets Ther 2021;14:5145-60. [PMID: 34720591 DOI: 10.2147/OTT.S272208] [Reference Citation Analysis]
204 Kristiansen TZ, Harsha HC, Grønborg M, Maitra A, Pandey A. Differential membrane proteomics using 18O-labeling to identify biomarkers for cholangiocarcinoma. J Proteome Res 2008;7:4670-7. [PMID: 18839982 DOI: 10.1021/pr800215n] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
205 Boonla C, Sripa B, Thuwajit P, Cha-On U, Puapairoj A, Miwa M, Wongkham S. MUC1 and MUC5AC mucin expression in liver fluke-associated intrahepatic cholangiocarcinoma. World J Gastroenterol 2005; 11(32): 4939-4946 [PMID: 16124042 DOI: 10.3748/wjg.v11.i32.4939] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.0] [Reference Citation Analysis]
206 Yao KJ, Jabbour S, Parekh N, Lin Y, Moss RA. Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health Statistics Database. BMC Gastroenterol. 2016;16:117. [PMID: 27655244 DOI: 10.1186/s12876-016-0527-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 5.2] [Reference Citation Analysis]
207 Chua D, Low A, Koh Y, Goh B, Cheow PC, Kam JH, Teo JY, Tan EK, Chung A, Ooi LL, Chan CY, Lee SY. A retrospective review of correlative radiological assessment and surgical exploration for hilar cholangiocarcinoma. Ann Hepatobiliary Pancreat Surg 2018;22:216-22. [PMID: 30215043 DOI: 10.14701/ahbps.2018.22.3.216] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
208 Zhang K, Chen D, Wang X, Zhang S, Wang J, Gao Y, Yan B. RNA interference targeting slug increases cholangiocarcinoma cell sensitivity to cisplatin via upregulating PUMA. Int J Mol Sci 2011;12:385-400. [PMID: 21339993 DOI: 10.3390/ijms12010385] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
209 Jiang X, Ma N, Wang D, Li F, He R, Li D, Zhao R, Zhou Q, Wang Y, Zhang F, Wan M, Kang P, Gao X, Cui Y. Metformin inhibits tumor growth by regulating multiple miRNAs in human cholangiocarcinoma. Oncotarget 2015;6:3178-94. [PMID: 25605008 DOI: 10.18632/oncotarget.3063] [Cited by in Crossref: 28] [Cited by in F6Publishing: 76] [Article Influence: 4.7] [Reference Citation Analysis]
210 Kohya N, Kitahara K, Miyazaki K. Rational therapeutic strategy for T2 gallbladder carcinoma based on tumor spread. World J Gastroenterol 2010; 16(28): 3567-3572 [PMID: 20653066 DOI: 10.3748/wjg.v16.i28.3567] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
211 Zhong W, Dai L, Liu J, Zhou S. Cholangiocarcinoma‑associated genes identified by integrative analysis of gene expression data. Mol Med Rep 2018;17:5744-53. [PMID: 29436659 DOI: 10.3892/mmr.2018.8594] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
212 Dolak W, Schwaighofer H, Hellmich B, Stadler B, Spaun G, Plieschnegger W, Hebenstreit A, Weber-Eibel J, Siebert F, Emmanuel K, Knoflach P, Gschwantler M, Vogel W, Trauner M, Püspök A; Austrian PDT study group. Photodynamic therapy with polyhematoporphyrin for malignant biliary obstruction: A nationwide retrospective study of 150 consecutive applications. United European Gastroenterol J 2017;5:104-10. [PMID: 28405328 DOI: 10.1177/2050640616654037] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
213 Bengala C, Bertolini F, Malavasi N, Boni C, Aitini E, Dealis C, Zironi S, Depenni R, Fontana A, Del Giovane C. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer. 2010;102:68-72. [PMID: 19935794 DOI: 10.1038/sj.bjc.6605458] [Cited by in Crossref: 147] [Cited by in F6Publishing: 143] [Article Influence: 11.3] [Reference Citation Analysis]
214 Liengswangwong U, Karalak A, Morishita Y, Noguchi M, Khuhaprema T, Srivatanakul P, Miwa M. Immunohistochemical expression of mismatch repair genes: A screening tool for predicting mutator phenotype in liver fluke infection-associated intrahepatic cholangiocarcinoma. World J Gastroenterol 2006; 12(23): 3740-3745 [PMID: 16773692 DOI: 10.3748/wjg.v12.i23.3740] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
215 Abdalla EK, Vauthey JN. Biliary tract cancer. Curr Opin Gastroenterol 2001;17:450-7. [PMID: 17031200 DOI: 10.1097/00001574-200109000-00009] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
216 Sung JE, Nam CW, Nah YW, Kim BS. Analysis of gallbladder polypoid lesion size as an indication of the risk of gallbladder cancer. Korean J Hepatobiliary Pancreat Surg 2014;18:9-13. [PMID: 26155240 DOI: 10.14701/kjhbps.2014.18.1.9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
217 Cidon EU. Resectable Cholangiocarcinoma: Reviewing the Role of Adjuvant Strategies. Clin Med Insights Oncol 2016;10:43-8. [PMID: 27199577 DOI: 10.4137/CMO.S32821] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
218 Zhong W, Tong Y, Li Y, Yuan J, Hu S, Hu T, Song G. Mesenchymal stem cells in inflammatory microenvironment potently promote metastatic growth of cholangiocarcinoma via activating Akt/NF-κB signaling by paracrine CCL5. Oncotarget 2017;8:73693-704. [PMID: 29088737 DOI: 10.18632/oncotarget.17793] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
219 Wei F, Shin D, Cai X. Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis. Int J Clin Oncol 2018;23:443-51. [PMID: 29289981 DOI: 10.1007/s10147-017-1231-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
220 Yu J, Shi L, Shen X, Zhao Y. UCP2 regulates cholangiocarcinoma cell plasticity via mitochondria-to-AMPK signals. Biochem Pharmacol 2019;166:174-84. [PMID: 31085159 DOI: 10.1016/j.bcp.2019.05.017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
221 Huguet JM, Lobo M, Labrador JM, Boix C, Albert C, Ferrer-Barceló L, Durá AB, Suárez P, Iranzo I, Gil-Raga M, Burgos CB, Sempere J. Diagnostic-therapeutic management of bile duct cancer. World J Clin Cases 2019; 7(14): 1732-1752 [PMID: 31417920 DOI: 10.12998/wjcc.v7.i14.1732] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
222 Zheng SL, Yip VS, Pedica F, Prachalias A, Quaglia A. Intrahepatic bile duct mixed adenoneuroendocrine carcinoma: a case report and review of the literature. Diagn Pathol. 2015;10:204. [PMID: 26589730 DOI: 10.1186/s13000-015-0439-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
223 Mahadevan A, Dagoglu N, Mancias J, Raven K, Khwaja K, Tseng JF, Ng K, Enzinger P, Miksad R, Bullock A, Evenson A. Stereotactic Body Radiotherapy (SBRT) for Intrahepatic and Hilar Cholangiocarcinoma. J Cancer. 2015;6:1099-1104. [PMID: 26516357 DOI: 10.7150/jca.13032] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 7.7] [Reference Citation Analysis]
224 Sang H, Li T, Li H, Liu J. Gab1 regulates proliferation and migration through the PI3K/Akt signaling pathway in intrahepatic cholangiocarcinoma. Tumour Biol 2015;36:8367-77. [PMID: 26014518 DOI: 10.1007/s13277-015-3590-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
225 Sang H, Li T, Li H, Liu J. Down-regulation of Gab1 inhibits cell proliferation and migration in hilar cholangiocarcinoma. PLoS One 2013;8:e81347. [PMID: 24312291 DOI: 10.1371/journal.pone.0081347] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
226 Ayaru L, Bown SG, Pereira SP. Photodynamic therapy for pancreatic and biliary tract carcinoma. Int J Gastrointest Cancer 2005;35:1-13. [PMID: 15722569 DOI: 10.1385/IJGC:35:1:001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
227 Manieri E, Folgueira C, Rodríguez ME, Leiva-Vega L, Esteban-Lafuente L, Chen C, Cubero FJ, Barrett T, Cavanagh-Kyros J, Seruggia D, Rosell A, Sanchez-Cabo F, Gómez MJ, Monte MJ, G Marin JJ, Davis RJ, Mora A, Sabio G. JNK-mediated disruption of bile acid homeostasis promotes intrahepatic cholangiocarcinoma. Proc Natl Acad Sci U S A 2020;117:16492-9. [PMID: 32601222 DOI: 10.1073/pnas.2002672117] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
228 Likhitrattanapisal S, Kumkate S, Ajawatanawong P, Wongprasert K, Tohtong R, Janvilisri T. Dysregulation of microRNA in cholangiocarcinoma identified through a meta-analysis of microRNA profiling. World J Gastroenterol 2020; 26(29): 4356-4371 [PMID: 32848339 DOI: 10.3748/wjg.v26.i29.4356] [Reference Citation Analysis]
229 Zhan M, Yang RM, Wang H, He M, Chen W, Xu SW, Yang LH, Liu Q, Long MM, Wang J. Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients. Cancer Commun (Lond) 2018;38:48. [PMID: 30016995 DOI: 10.1186/s40880-018-0318-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
230 Wang W, Zhong W, Yuan J, Yan C, Hu S, Tong Y, Mao Y, Hu T, Zhang B, Song G. Involvement of Wnt/β-catenin signaling in the mesenchymal stem cells promote metastatic growth and chemoresistance of cholangiocarcinoma. Oncotarget. 2015;6:42276-42289. [PMID: 26474277 DOI: 10.18632/oncotarget.5514] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 7.3] [Reference Citation Analysis]
231 Boozari B, Lotz J, Galanski M, Gebel M. Diagnostic imaging of liver tumours. Current status. Internist (Berl). 2007;48:8, 10-2, 14-6, 18-20. [PMID: 17216509 DOI: 10.1007/s00108-006-1773-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
232 Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2002;2:10. [PMID: 11991810 DOI: 10.1186/1471-2407-2-10] [Cited by in Crossref: 314] [Cited by in F6Publishing: 297] [Article Influence: 15.7] [Reference Citation Analysis]
233 Collins AL, Wojcik S, Liu J, Frankel WL, Alder H, Yu L, Schmittgen TD, Croce CM, Bloomston M. A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma. Ann Surg Oncol 2014;21:133-8. [PMID: 24046106 DOI: 10.1245/s10434-013-3240-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
234 Huang D, Joo H, Song N, Cho S, Kim W, Shin A. Association between gallstones and the risk of biliary tract cancer: a systematic review and meta-analysis. Epidemiol Health 2021;43:e2021011. [PMID: 33541011 DOI: 10.4178/epih.e2021011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
235 Moole H, Dharmapuri S, Duvvuri A, Dharmapuri S, Boddireddy R, Moole V, Yedama P, Bondalapati N, Uppu A, Yerasi C. Endoscopic versus Percutaneous Biliary Drainage in Palliation of Advanced Malignant Hilar Obstruction: A Meta-Analysis and Systematic Review. Can J Gastroenterol Hepatol 2016;2016:4726078. [PMID: 27648439 DOI: 10.1155/2016/4726078] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
236 Salvador VB, Samrao P, Leytin A, Basith M. Atypical presentation of an advanced obstructive biliary cancer without jaundice. Am J Case Rep 2013;14:462-6. [PMID: 24223234 DOI: 10.12659/AJCR.889620] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
237 Assy N, Assy N, Samuel N, Lerman A, Nseir W. Approach to Solid Liver Masses in the Cirrhotic Patient. Gastroenterology Res 2009;2:259-67. [PMID: 27956969 DOI: 10.4021/gr2009.10.1314] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
238 Liu ZH, He YP, Qin H. The growth-inhibition effect of tamoxifen in the combination chemotherapeutics on the human cholangiocarcinoma cell line QBC939. Mol Biol Rep 2010;37:2693-701. [PMID: 19757172 DOI: 10.1007/s11033-009-9801-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
239 Dahlstrand U, Sandblom G, Eriksson LG, Nyman R, Rasmussen IC. Primary patency of percutaneously inserted self-expanding metallic stents in patients with malignant biliary obstruction. HPB (Oxford). 2009;11:358-363. [PMID: 19718365 DOI: 10.1111/j.1477-2574.2009.00069.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
240 Okaniwa S. How Can We Manage Gallbladder Lesions by Transabdominal Ultrasound? Diagnostics (Basel) 2021;11:784. [PMID: 33926095 DOI: 10.3390/diagnostics11050784] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
241 Pisarello MJ, Loarca L, Ivanics T, Morton L, LaRusso N. MicroRNAs in the Cholangiopathies: Pathogenesis, Diagnosis, and Treatment. J Clin Med 2015;4:1688-712. [PMID: 26343736 DOI: 10.3390/jcm4091688] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
242 Andreotti G, Chen J, Gao YT, Rashid A, Chang SC, Shen MC, Wang BS, Han TQ, Zhang BH, Danforth KN. Serum lipid levels and the risk of biliary tract cancers and biliary stones: A population-based study in China. Int J Cancer. 2008;122:2322-2329. [PMID: 18076041 DOI: 10.1002/ijc.23307] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 3.6] [Reference Citation Analysis]
243 Weber A, Landrock S, Schneider J, Stangl M, Neu B, Born P, Classen M, Rösch T, Schmid RM, Prinz C. Long-term outcome and prognostic factors of patients with hilar cholangiocarcinoma. World J Gastroenterol 2007; 13(9): 1422-1426 [PMID: 17457974 DOI: 10.3748/wjg.v13.i9.1422] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
244 Fingas CD, Blechacz BR, Smoot RL, Guicciardi ME, Mott J, Bronk SF, Werneburg NW, Sirica AE, Gores GJ. A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells. Hepatology 2010;52:550-61. [PMID: 20683954 DOI: 10.1002/hep.23729] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
245 Blair AB, Murphy A. Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future. Curr Probl Cancer. 2018;42:49-58. [PMID: 29501212 DOI: 10.1016/j.currproblcancer.2017.10.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
246 Fisher SB, Fisher KE, Maithel SK. Molecular targeted therapy for biliary tract malignancy: defining the target. Hepatobiliary Surg Nutr 2012;1:53-4. [PMID: 24570902 DOI: 10.3978/j.issn.2304-3881.2012.10.02] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
247 Alexopoulou A, Soultati A, Dourakis SP, Vasilieva L, Archimandritis AJ. Cholangiocarcinoma: A 7-year experience at a single center in Greece. World J Gastroenterol 2008; 14(40): 6213-6217 [PMID: 18985813 DOI: 10.3748/wjg.14.6213] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
248 Andreotti G, Chen J, Gao YT, Rashid A, Chen BE, Rosenberg P, Sakoda LC, Deng J, Shen MC, Wang BS. Polymorphisms of genes in the lipid metabolism pathway and risk of biliary tract cancers and stones: a population-based case-control study in Shanghai, China. Cancer Epidemiol Biomarkers Prev. 2008;17:525-534. [PMID: 18296645 DOI: 10.1158/1055-9965.epi-07-2704] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
249 Spizzo G, Puccini A, Xiu J, Goldberg RM, Grothey A, Shields AF, Arora SP, Khushman M, Salem ME, Battaglin F, Baca Y, El-Deiry WS, Philip PA, Nassem M, Hall M, Marshall JL, Kocher F, Amann A, Wolf D, Korn WM, Lenz HJ, Seeber A. Molecular profile of BRCA-mutated biliary tract cancers. ESMO Open 2020;5:e000682. [PMID: 32576609 DOI: 10.1136/esmoopen-2020-000682] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 22.0] [Reference Citation Analysis]
250 Chapman MH, Sandanayake NS, Andreola F, Dhar DK, Webster GJ, Dooley JS, Pereira SP. Circulating CYFRA 21-1 is a Specific Diagnostic and Prognostic Biomarker in Biliary Tract Cancer. J Clin Exp Hepatol. 2011;1:6-12. [PMID: 22228935 DOI: 10.1016/s0973-6883(11)60110-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
251 Fingas CD, Mertens JC, Razumilava N, Sydor S, Bronk SF, Christensen JD, Rizvi SH, Canbay A, Treckmann JW, Paul A, Sirica AE, Gores GJ. Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma. Hepatology 2013;58:1362-74. [PMID: 23703673 DOI: 10.1002/hep.26484] [Cited by in Crossref: 28] [Cited by in F6Publishing: 76] [Article Influence: 3.1] [Reference Citation Analysis]
252 Xu HX, Wang Y, Lu MD, Liu LN. Percutaneous ultrasound-guided thermal ablation for intrahepatic cholangiocarcinoma. Br J Radiol. 2012;85:1078-1084. [PMID: 22374282 DOI: 10.1259/bjr/24563774] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
253 Furukawa H, Ikuma H, Asakura-Yokoe K, Uesaka K. Preoperative staging of biliary carcinoma using 18F-fluorodeoxyglucose PET: prospective comparison with PET+CT, MDCT and histopathology. Eur Radiol. 2008;18:2841-2847. [PMID: 18509655 DOI: 10.1007/s00330-008-1062-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
254 Zong H, Zhou H, Xiang Y, Wu G. miR-125b suppresses cellular proliferation by targeting c-FLIP in gallbladder carcinoma. Oncol Lett 2019;18:6822-8. [PMID: 31788125 DOI: 10.3892/ol.2019.11000] [Reference Citation Analysis]
255 Ocean AJ, Christos P, Sparano JA, Matulich D, Kaubish A, Siegel A, Sung M, Ward MM, Hamel N, Espinoza-Delgado I, Yen Y, Lane ME. Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2011;68:379-88. [PMID: 20981545 DOI: 10.1007/s00280-010-1481-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
256 Lubner SJ, Mahoney MR, Kolesar JL, Loconte NK, Kim GP, Pitot HC, Philip PA, Picus J, Yong WP, Horvath L, Van Hazel G, Erlichman CE, Holen KD. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol. 2010;28:3491-3497. [PMID: 20530271 DOI: 10.1200/jco.2010.28.4075] [Cited by in Crossref: 163] [Cited by in F6Publishing: 82] [Article Influence: 13.6] [Reference Citation Analysis]
257 Yoon HA, Noh MH, Kim BG, Han JS, Jang JS, Choi SR, Jeong JS, Chun JH. Clinicopathological significance of altered Notch signaling in extrahepatic cholangiocarcinoma and gallbladder carcinoma. World J Gastroenterol 2011; 17(35): 4023-4030 [PMID: 22046092 DOI: 10.3748/wjg.v17.i35.4023] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
258 Iwahashi S, Shimada M, Utsunomiya T, Morine Y, Imura S, Ikemoto T, Mori H, Hanaoka J. Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in gallbladder carcinoma. Surg Today. 2012;42:565-569. [PMID: 22270332 DOI: 10.1007/s00595-012-0118-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
259 Shah UA, Nandikolla AG, Rajdev L. Immunotherapeutic Approaches to Biliary Cancer. Curr Treat Options Oncol 2017;18:44. [PMID: 28660602 DOI: 10.1007/s11864-017-0486-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
260 Woo SM, Lee SH, Yoo JW, Yang KY, Seo JG, Park JK, Hwang JH, Lee WJ, Ryu JK, Kim YT, Yoon YB. A Multicenter Phase II Trial of Gemcitabine Plus Oxaliplatin in Unresectable Gallbladder Cancer. Gut Liver 2013;7:594-8. [PMID: 24073318 DOI: 10.5009/gnl.2013.7.5.594] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
261 Fareed MM, DeMora L, Esnaola NF, Denlinger CS, Karachristos A, Ross EE, Hoffman J, Meyer JE. Concurrent chemoradiation for resected gall bladder cancers and cholangiocarcinomas. J Gastrointest Oncol. 2018;9:762-768. [PMID: 30151273 DOI: 10.21037/jgo.2018.05.09] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
262 Balian A, Montembault S, Raynard B, Maitre S, Capron F, Chaput JC, Naveau S. Gallbladder carcinoma secondary to repetitive hepatic arterial chemoembolization. Am J Gastroenterol 2002;97:1079-80. [PMID: 12003407 DOI: 10.1111/j.1572-0241.2002.05648.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
263 Keane MG, Shah A, Pereira SP, Joshi D. Novel biomarkers and endoscopic techniques for diagnosing pancreaticobiliary malignancy. F1000Res. 2017;6:1643. [PMID: 28944047 DOI: 10.12688/f1000research.11371.1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
264 Lauterio A, De Carlis R, Centonze L, Buscemi V, Incarbone N, Vella I, De Carlis L. Current Surgical Management of Peri-Hilar and Intra-Hepatic Cholangiocarcinoma. Cancers (Basel) 2021;13:3657. [PMID: 34359560 DOI: 10.3390/cancers13153657] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
265 Li C, Li X, Wu L, Jiang Z. Elevated AQP1 Expression Is Associated With Unfavorable Oncologic Outcome in Patients With Hilar Cholangiocarcinoma. Technol Cancer Res Treat 2017;16:421-7. [PMID: 27143047 DOI: 10.1177/1533034616646288] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
266 Chun JW, Lee B, Park WS, Han N, Hong EK, Park EY, Han SS, Park SJ, Kim TH, Lee WJ, Woo SM. RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin. J Clin Med 2021;10:4652. [PMID: 34682775 DOI: 10.3390/jcm10204652] [Reference Citation Analysis]
267 Brown KM, Parmar AD, Geller DA. Intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am. 2014;23:231-246. [PMID: 24560108 DOI: 10.1016/j.soc.2013.10.004] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
268 Hirashita T, Iwashita Y, Ohta M, Komori Y, Eguchi H, Yada K, Kitano S. Expression of matrix metalloproteinase-7 is an unfavorable prognostic factor in intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2012;16:842-848. [PMID: 22246855 DOI: 10.1007/s11605-011-1813-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
269 Vanderveen KA, Hussain HK. Magnetic Resonance Imaging of cholangiocarcinoma. Cancer Imaging. 2004;4:104-115. [PMID: 18250017 DOI: 10.1102/1470-7330.2004.0018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
270 Cha JM, Kim MH, Jang SJ. Early bile duct cancer. World J Gastroenterol 2007; 13(25): 3409-3416 [PMID: 17659686 DOI: 10.3748/wjg.v13.i25.3409] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
271 Dowlati A, Posey J, Ramanathan RK, Rath L, Fu P, Chak A, Krishnamurthi S, Brell J, Ingalls S, Hoppel CL, Ivy P, Remick SC. Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers. Cancer Chemother Pharmacol 2009;65:73-8. [PMID: 19399502 DOI: 10.1007/s00280-009-1005-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
272 Gabriel E, Gandhi S, Attwood K, Kuvshinoff B, Hochwald S, Iyer R. Gemcitabine and capecitabine for advanced biliary cancer. J Gastrointest Oncol 2017;8:728-36. [PMID: 28890824 DOI: 10.21037/jgo.2017.01.24] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
273 Park J, Kim MH, Kim KP, Park DH, Moon SH, Song TJ, Eum J, Lee SS, Seo DW, Lee SK. Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study. Gut Liver. 2009;3:298-305. [PMID: 20431764 DOI: 10.5009/gnl.2009.3.4.298] [Cited by in Crossref: 104] [Cited by in F6Publishing: 89] [Article Influence: 8.0] [Reference Citation Analysis]
274 Fornaro L, Vivaldi C, Cereda S, Leone F, Aprile G, Lonardi S, Silvestris N, Santini D, Milella M, Caparello C, Musettini G, Pasquini G, Falcone A, Brandi G, Sperduti I, Vasile E; GICO group (Gruppo Italiano COlangiocarcinoma). Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. J Exp Clin Cancer Res. 2015;34:156. [PMID: 26693938 DOI: 10.1186/s13046-015-0267-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]